Company intelligence / Profile preview

Progentos Therapeutics

Watertown, Massachusetts, United Statesprogentos.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Progentos is developing first-in-class small molecules designed to induce remyelination of axons affected by MS. Their proprietary molecules outperform previous approaches in differentiating oligodendrocyte progenitor cells to generate new oligodendrocytes and regenerate myelin in in vivo models[2][7].

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Beyond the preview

Go deeper on Progentos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Progentos Therapeutics.

Explore the full profile